Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2012-09-26 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Receives Maximum Extension to German Patent 2 pages 83.8KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Pharmaxis has received a maximum extension of term to a major European patent for its products Aridol and Bronchitol. It discusses the granting of a Supplementary Protection Certificate (SPC) by the German Patent Office, extending patent protection by five years. The content is focused on patent and product protection news, not on financial results, management changes, or regulatory filings. It is a corporate announcement related to intellectual property rights and product market protection. The document is not a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate announcement, which corresponds to Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2012-09-26 English
Investor Presentation 31 pages 5.0MB
Investor Presentation Classification · 95% confidence The document is a detailed company overview and product pipeline presentation for Pharmaxis, focusing on respiratory disease products such as Aridol and Bronchitol. It includes clinical trial data, regulatory approval status, market introduction plans, and commercialisation priorities. The content is structured as a presentation with figures and images, discussing product development, clinical trials, regulatory submissions (e.g., NDA submission to FDA), and market strategy. There is no indication that this is a formal financial report, audit report, earnings release, or regulatory filing. The document is not a transcript of a call, nor a voting result or director dealing. It is a comprehensive investor or corporate presentation aimed at informing stakeholders about the company's products, clinical progress, and market plans. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2012-09-12 English
Notice of Annual General Meeting/Proxy Form 2012 12 pages 657.6KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF THE 2012 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and contains detailed information about the upcoming Annual General Meeting (AGM) including date, location, agenda items such as financial statements, remuneration report, re-election of directors, and grant of performance rights and options. It also includes proxy voting instructions and explanatory notes for each agenda item. The document is clearly a notice and explanatory statement for the AGM, not the actual annual report or financial statements themselves. It is a communication sent to shareholders to inform them about the AGM and solicit their votes. Therefore, this document fits the category of AGM Information (AGM-R).
2012-09-10 English
Annual Report to shareholders 2012 95 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled '2012 Statutory Annual Report' and includes detailed sections typical of an annual report such as Directors' report, financial statements, remuneration report, corporate governance, senior management, operating and financial review, auditor's report, and shareholder information. It references lodging with the Australian Securities Exchange and the Australian Securities and Investments Commission, which is consistent with regulatory requirements for annual reports. The length of the document (15,000 characters) and the presence of comprehensive financial and operational information confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2012
2012-09-10 English
Investor Presentation 33 pages 4.7MB
Investor Presentation Classification · 95% confidence The document is a detailed company overview and product development presentation from August 2012 for Pharmaxis, focusing on respiratory disease products such as Bronchitol and Aridol. It includes clinical trial data, regulatory status updates (e.g., FDA NDA submission and review timelines), market launch plans, reimbursement status, manufacturing and commercial infrastructure, and pipeline development. The content is structured as a comprehensive presentation with charts, images, and detailed descriptions of products, clinical programs, and market strategies. There is no indication that this is an official annual or interim financial report, audit report, earnings release, or regulatory filing. It is not a transcript of a call or a voting result announcement. The document is clearly designed to inform investors or stakeholders about the company's products, clinical progress, and commercial plans, which fits the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content confirm it is the presentation itself, not just an announcement of a report publication.
2012-08-15 English
Preliminary Final Report 47 pages 253.0KB
Annual Report Classification · 100% confidence The document is titled 'ASX Preliminary Final Report – 30 June 2012' and includes detailed financial data such as consolidated income statement, statement of comprehensive income, balance sheet, cash flows, and notes to the financial statements. It covers the full fiscal year ended 30 June 2012 and includes management commentary on operations, sales, R&D expenses, and other financial metrics. The document also references the audit status and states that the audit report is unqualified and will be included in the statutory annual report. The length of the document (15,000 characters) and the presence of comprehensive financial statements and analysis confirm it is a full annual report rather than a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2012
2012-08-09 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.